RTW INVESTMENTS, LPRTW INVESTMENTS, LP

Institutional investor · Portfolio as of Q4 2019

SEC EDGAR SourceSEC Filings

Top Holdings61 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction

ROCKET PHARMACEUTICALS INC

16.8M$382.7M14.4%$17.53+31.88%
4 qtrssince 2019-Q1
Increased
61

ALNYLAM PHARMACEUTICALS INC

1.6M$188.6M7.1%$80.50+42.47%
4 qtrssince 2019-Q1
Decreased
0

PTC THERAPEUTICS INC

3.8M$184.1M6.9%$38.90+22.24%
4 qtrssince 2019-Q1
Increased
62
DRNADRNADelisted

DICERNA PHARMACEUTICALS INC

5.9M$129.4M4.9%
4 qtrssince 2019-Q1
Decreased
0

AXSOME THERAPEUTICS INC

1M$106.1M4.0%$32.80+216.55%
4 qtrssince 2019-Q1
Increased
66

BRISTOL-MYERS SQUIBB CO

1.6M$105.5M4.0%$37.30+34.81%
4 qtrssince 2019-Q1
Increased
58

STOKE THERAPEUTICS INC

3.5M$100.4M3.8%$29.08-5.24%
3 qtrssince 2019-Q2
Increased
58
4.3M$90M3.4%
4 qtrssince 2019-Q1
Increased
83
MRTXMRTXDelisted

MIRATI THERAPEUTICS INC

645,427$83.2M3.1%
4 qtrssince 2019-Q1
Increased
60

AVI BIOPHARMA INC

605,762$78.2M2.9%$123.90+3.95%
4 qtrssince 2019-Q1
Decreased
0
ADVMADVMDelisted

ADVERUM BIOTECHNOLOGIES INC

6.4M$73.6M2.8%

IMMUNOVANT INC

4.4M$66M2.5%$15.810.00%
1 qtr
New
76

ZIMMER HOLDINGS INC

437,385$65.5M2.5%$124.90+10.11%
2 qtrssince 2019-Q3
Increased
55

MILESTONE PHARMACEUTICALS IN

4M$63.4M2.4%$25.87-39.97%
3 qtrssince 2019-Q2
Increased
57
MASIMASIDelisted

MASIMO CORP

382,187$60.4M2.3%$139.11+14.01%
4 qtrssince 2019-Q1
Increased
52

ESTABLISHMENT LABS HLDGS INC

2M$56.2M2.1%$23.06+17.74%
4 qtrssince 2019-Q1
Decreased
0
MYOKMYOKDelisted

MYOKARDIA INC

760,988$55.5M2.1%
4 qtrssince 2019-Q1
Increased
53

VERICEL CORP

3M$52M2.0%$17.50-1.44%
4 qtrssince 2019-Q1
Increased
52

PROQR THRAPEUTICS N V

4.8M$47.4M1.8%$12.87-26.59%
4 qtrssince 2019-Q1
Increased
58
AXNXAXNXDelisted

AXONICS INC

1.6M$44.1M1.7%
4 qtrssince 2019-Q1
Increased
48
$2.7B
AUM
61
Positions
Q4 2019
Filing
Rating · 3.0
Quarterly Portfolio Change
+28%Q2'19$1.9B-10%Q3'19$1.7B+58%Q4'19$2.7B
Activity profile
$ moved · Q4'19
New19%Increased60%Decreased16%Exited6%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.0 quarters
<1Q18%1-4Q82%1-2Y0%2Y+0%

RTW INVESTMENTS, LP manages $2.7B across 61 positions as of Q4 2019. Top holdings: RCKT (14.4%), ALNY (7.1%), PTCT (6.9%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 3/5.0.

Q4 2019 Summary

Active quarter - 13 new positions, 12 exits, 31 increased. Top move: IMVT (NEW, conviction 76). Portfolio: $2.7B across 61 positions.

Top holdings by portfolio weight

Total AUM$3B
RCKT14.44%
ALNY7.12%
PTCT6.95%
DRNA4.88%
AXSM4.00%
BMY3.98%
STOK3.79%
HOMOLOGY MED3.40%
MRTX3.14%
SRPT2.95%
Other2.78%

Portfolio allocation by GICS sector

Sectors2
Healthcare77.70%
Unknown22.30%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare, Unknown
Compare DNA across all funds
7-dimension quality assessment
Solid(3.0 / 5.0)
Track Record36
Conviction45
Concentration72
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
7Q
RDNTRDNTRadNet, Inc.
Q4 2024 Q2 2026+3M shares+$173.4M
6Q
CMPSCMPSCOMPASS PATHWAYS PLC
Q1 2025 Q2 2026+7.6M shares+$139.7M
6Q
IMTXIMTXIMMATICS N.V
Q1 2025 Q2 2026+6.4M shares+$84.6M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used